Literature DB >> 15679808

Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.

Vasilios E Theodoropoulos1, Andreas C Lazaris, Ioannis Kastriotis, Chariclia Spiliadi, George E Theodoropoulos, Vasiliki Tsoukala, Efstratios Patsouris, Frank Sofras.   

Abstract

OBJECTIVES: To investigate the possible role of hypoxia-inducible factor 1alpha (HIF-1alpha, a transcription factor important in regulating O(2) homeostasis and physiological responses to oxygen deprivation) in the recurrence and progression of superficial urothelial bladder cancer, and to examine its expression in relation to proliferation status, apoptotic activity and intratumoral angiogenesis. PATIENTS AND METHODS: Paraffin wax-embedded tissue from 140 patients with superficial primary urothelial bladder carcinoma was immunostained for HIF-1alpha, Ki-67, single-stranded DNA antibody for apoptotic cells, p53, bcl-2, vascular endothelial growth factor and CD31 antigen. We calculated the proliferative rate, the apoptotic index and the microvessel density (MVD). The mean (sem) follow-up was 46 (3.5) months, within which 86 patients relapsed while 18 progressed to a higher tumour stage and/or grade.
RESULTS: HIF-1alpha expression was more common in high-grade superficial urothelial carcinomas. The positivity was related to increased proliferative activity (P = 0.012), apoptotic rate (P = 0.006) and MVD (P < 0.001). HIF-1alpha overexpression had a marginal adverse influence on progression-free survival (P = 0.058; univariate analysis), but when combined with p53 overexpression, the unfavourable impact was statistically important (P = 0.028). In multivariate analysis, only grade and the high Ki-67 labelling index were significant predictors of recurrence-free survival, while T-stage and the HIF-1alpha+/p53+ phenotype emerged as the only independent variables of adverse prognostic significance for time to progression.
CONCLUSIONS: HIF-1alpha overexpression combined with aberrant mutant p53 nuclear protein accumulation seem to indicate an aggressive phenotype, suggesting a potential biological model predictive of future risk of disease progression in patients with superficial urothelial bladder carcinoma. These indicators may be helpful in clinical practice to discriminate superficial bladder cancer worth a more intensive follow-up, or more aggressive treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15679808     DOI: 10.1111/j.1464-410X.2005.05314.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  24 in total

1.  HIF-1α and GLUT-1 Expression in Atypical Endometrial Hyperplasia, Type I and II Endometrial Carcinoma: A Potential Role in Pathogenesis.

Authors:  Dalia Rifaat Al-Sharaky; Asmaa Gaber Abdou; Moshira Mohammed Abdel Wahed; Hend Abdou Kassem
Journal:  J Clin Diagn Res       Date:  2016-05-01

Review 2.  Imaging angiogenesis of genitourinary tumors.

Authors:  Ying-Kiat Zee; James P B O'Connor; Geoff J M Parker; Alan Jackson; Andrew R Clamp; M Ben Taylor; Noel W Clarke; Gordon C Jayson
Journal:  Nat Rev Urol       Date:  2010-01-19       Impact factor: 14.432

3.  UHRF1 is associated with tumor recurrence in non-muscle-invasive bladder cancer.

Authors:  Guo-Liang Yang; Lian-Hua Zhang; Juan-Jie Bo; Hai-Ge Chen; Ming Cao; Dong-Ming Liu; Yi-Ran Huang
Journal:  Med Oncol       Date:  2011-05-25       Impact factor: 3.064

4.  Angiogenesis in upper tract urothelial carcinoma associated with Balkan endemic nephropathy.

Authors:  Ljubinka Jankovic Velickovic; Ana Ristic Petrovic; Slavica Stojnev; Zana Dolicanin; Takanori Hattori; Hiroyuki Sugihara; Ken-ichi Mukaisho; Mariola Stojanovic; Vladisav Stefanovic
Journal:  Int J Clin Exp Pathol       Date:  2012-09-05

Review 5.  Expression profiling for bladder cancer: strategies to uncover prognostic factors.

Authors:  Georg Bartsch; Anirban P Mitra; Richard J Cote
Journal:  Expert Rev Anticancer Ther       Date:  2010-12       Impact factor: 4.512

6.  Expression of fibroblast growth factor receptor 3 in the recurrence of non-muscle-invasive urothelial carcinoma of the bladder.

Authors:  Young-Hee Maeng; Su-Yong Eun; Jung-Sik Huh
Journal:  Korean J Urol       Date:  2010-02-18

Review 7.  Targeting vasculature in urologic tumors: mechanistic and therapeutic significance.

Authors:  Shinichi Sakamoto; A Jacqueline Ryan; Natasha Kyprianou
Journal:  J Cell Biochem       Date:  2008-02-15       Impact factor: 4.429

8.  Evaluation of relationship between HIF-1alpha immunoreactivity and stage, grade, angiogenic profile and proliferative index in bladder urothelial carcinomas.

Authors:  Hale Deniz; Metin Karakök; Faruk Yagci; Muhammet Emin Güldür
Journal:  Int Urol Nephrol       Date:  2009-05-30       Impact factor: 2.370

Review 9.  [Urine-based markers of angiogenesis in bladder cancer].

Authors:  M Becker; D Tilki; T Szarvas; H Rübben; S Ergün
Journal:  Urologe A       Date:  2009-06       Impact factor: 0.639

Review 10.  Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics.

Authors:  G L Semenza
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.